Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Oropharyngeal Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Linavonkibart’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Linavonkibart is expected to reach an annual total of $37 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Linavonkibart Overview
SRK-181 is under development for the treatment of solid tumors including but not limited to bladder cancer, myelofibrosis, head and neck squamous cell carcinoma (HNSCC), urothelial cancer, non-small cell lung cancer, melanoma, clear cell renal cell carcinoma (ccRCC), myelofibrosis , breast cancer and ovarian cancer and oropharyngeal cancer. It acts by targeting transforming growth factor beta 1 (TGFB1). The drug candidate is developed using the supracellular activation technology platform.
Scholar Rock Holding Overview
Scholar Rock Holding (Scholar Rock) is a clinical-stage biopharmaceutical company that develops novel medicines for the treatment of severe diseases in which signaling by protein growth factors plays a fundamental role. The company’s pipeline products comprise SRK-015, an inhibitor for the treatment of spinal muscular atrophy (SMA). It also develops inhibitors of latent TGFß1 for the treatment of immune oncology and fibrosis. Scholar Rock serves in the therapeutic areas of neuromuscular disorders, fibrosis, cancer and also anemia. The company has collaborated with Gilead Sciences Inc to discover and develop specific inhibitors. Scholar Rock is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$33.2 million for the fiscal year ended December 2022 (FY2022), an increase of 76.4% over FY2021. The operating loss of the company was US$134.4 million in FY2022, compared to an operating loss of US$129.9 million in FY2021. The net loss of the company was US$134.5 million in FY2022, compared to a net loss of US$131.8 million in FY2021.
For a complete picture of Linavonkibart’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
